Overview Financials News + Filings Key Docs Ownership
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
Adagene Inc.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
09/29/2023 |
6-K
| Quarterly results |
07/07/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/04/2023 |
6-K
| Quarterly results |
04/28/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
04/18/2023 |
6-K
| Quarterly results |
03/28/2023 |
6-K
| Quarterly results |
01/09/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
12/16/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
11/21/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
09/12/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
08/31/2022 |
6-K
| Quarterly results |
06/29/2022 |
6-K
| Quarterly results |
05/26/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
04/08/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
03/31/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
03/16/2022 |
6-K
| Quarterly results |
03/09/2022 |
6-K
| Quarterly results |
03/02/2022 |
6-K
| Quarterly results |
01/27/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
|
"FORM 6-K",
"Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116 SAN DIEGO and SUZHOU, China, January 27, 2022 - Adagene Inc. , a company transforming the discovery and development of novel antibody-based therapies, today announced the first patient has been dosed in a combination cohort of its anti-CD137 agonist, ADG106, with its anti-CTLA-4 monoclonal antibody , ADG116, in patients with advanced/metastatic solid tumors. The dose escalation cohort will evaluate the safety and tolerability of this novel, proprietary combination in patients with advanced/metastatic solid tumors. “Existing cancer therapies that target CD137 and CTLA-4 are associated with safety concerns, creating a significant unmet need and ..." |
|
01/19/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
01/13/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
01/12/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
12/22/2021 |
6-K
| Quarterly results |
12/14/2021 |
6-K
| Quarterly results |
12/07/2021 |
6-K
| Quarterly results |
12/06/2021 |
6-K
| Quarterly results |
11/29/2021 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
11/23/2021 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
11/04/2021 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
10/27/2021 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
08/26/2021 |
6-K
| Quarterly results |
08/19/2021 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
08/12/2021 |
6-K
| Quarterly results |
07/22/2021 |
6-K
| Quarterly results |
|
|
|